Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314383 | 1.00 | MAPT (0.38) | MAPTALDH1A1PKMIDO1LMNA | |
| SCHEMBL11881437 | 0.86 | ALDH1A1 (0.46) | ALDH1A1PKMCYP1A1CYP1B1FFAR4 | |
| SCHEMBL3038765 | 0.86 | ALDH1A1 (0.52) | ALDH1A1PKMLMNACYP1A1CYP1B1 | |
| SCHEMBL24156677 | 0.82 | SMN1; SMN2 (0.39) | MAPTALDH1A1PKMIDO1LMNA | |
| SCHEMBL30253355 | 0.82 | SMN1; SMN2 (0.39) | MAPTALDH1A1PKMIDO1LMNA | |
| SCHEMBL24269950 | 0.80 | PTGDR (0.36) | ALDH1A1FFAR4MMP9 | |
| SCHEMBL309556 | 0.79 | LMNA (0.40) | MAPTALDH1A1PKMIDO1LMNA | |
| SCHEMBL11048238 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MMP1MMP9MMP13 | |
| SCHEMBL197622 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MMP1MMP9MMP13 | |
| SCHEMBL24884699 | 0.79 | KDM4E (0.38) | MAPTALDH1A1LMNAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | BEIGENE, LTD. (KY) | 2025-01-14 | — | — | US | disclosed |
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| CN-117624131-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117624130-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| EP-4222150-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BeiGene, Ltd. (KY) | 2023-08-09 | — | — | EP | disclosed |
| CN-116323565-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3464292-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| US-10662200-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10479797-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190292196-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-19 | — | — | US | disclosed |
| EP-3464292-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017214002-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-8722656-B2 | Cephalosporins useful as antibacterial agents | ZOETIS LLC (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2705044-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | ZOETIS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012150520-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120283237-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | MAPT 3979/4885ALDH1A1 3197/4885PKM 383/4885 |
| US-10479797-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | MAPT 4632/4885ALDH1A1 333/4885PKM 3124/4885 |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | MAPT 3979/4885ALDH1A1 3197/4885PKM 383/4885 |
| US-20190292196-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | MAPT 4632/4885ALDH1A1 333/4885PKM 3124/4885 |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | MAPT 4632/4885ALDH1A1 333/4885PKM 3124/4885 |
| US-10662200-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | MAPT 4632/4885ALDH1A1 333/4885PKM 3124/4885 |
| US-20120283237-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | CIAPIN1, CLSPN, MRPL21 | MAPT 4673/4885ALDH1A1 3155/4885PKM 4448/4885 |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | MAPT 4632/4885ALDH1A1 333/4885PKM 3124/4885 |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | HIPK1, HIPK3, HIPK2 | MAPT 3979/4885ALDH1A1 3197/4885PKM 383/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | MAPT 3926/4885ALDH1A1 3156/4885PKM 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.